ClinicalTrials.gg
CompletedNCT07764653Updated Aug 14, 2026

Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer

A Phase 3 interventional study of Technetium Tc 99m Sulfur Colloid Injection and Mitoxantrone Hydrochloride Injection for Tracing in Sentinel Nodes and Breast Cancer, sponsored by HTA Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by HTA Co., Ltd. · Phase 3, Interventional, and Diagnostic

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Jan 2024, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
213
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
538th of 1,519
213 · median 120
Started
2024
with 221 others
Phase 3
331 of 1,928
120 open now
Registered
1,868th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 538th largest by enrollment of the 1,519 interventional ones that give a count, is one of 222 that started in 2024, is one of 331 in phase 3, and was the 1,868th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The aim of the study is a prospective multicentre phase-3 study that aims to evaluate the detection rate of sentinel lymph node in patients with breast cancer.

To compare the detection rates of Technetium Tc 99m Sulfur Colloid Injection(99mTc-SC) and Mitoxantrone Hydrochloride Injection for Tracing(MHI) for lymphatic tracing in patients with breast cancer.

Read the detailed description

All enrolled subjects with breast cancer will receive Technetium Tc 99m Sulfur Colloid Injection and Mitoxantrone Hydrochloride Injection for Tracing sequentially, to evaluate the efficacy of the two methods for sentinel lymph node (SLN) mapping in breast cancer patients. Due to the characteristics of the investigational product and sentinel lymph node biopsy (SLNB) procedure, blinding is not feasible for this trial; therefore, an open-label design is adopted.

At least 8 subjects will be enrolled in the initial exploratory phase to investigate the lymph node uptake of 99mTc-SC, and to determine the optimal administration time, dosage, and preoperative SPECT/CT imaging schedule. These 8 subjects will not be included in the final efficacy and safety analysis set, and an additional 8 subjects will be enrolled subsequently.

  • At least 4 subjects will receive no more than 0.5 mCi of Technetium Tc 99m Sulfur Colloid Injection at 6 h ± 36 min before surgery. Dynamic scintigraphy (5 min per frame, with supplementary lateral imaging of the ipsilateral side) will be performed for 60 minutes as soon as possible (2-3 min) after injection. Planar static imaging (anterior and ipsilateral lateral views) of the ipsilateral breast and axillary regions will be conducted at 2 h ± 12 min and 3 h ± 18 min, and SPECT/CT imaging (anterior view, ipsilateral lateral view, and tomographic scan) will be performed at 5 h ± 30 min, for a total of 4 scans.
  • At least 4 subjects will receive no more than 1 mCi of Technetium Tc 99m Sulfur Colloid Injection at 18 h ± 120 min before surgery. Dynamic scintigraphy within 60 minutes (5 min per frame, with supplementary lateral imaging of the ipsilateral side) will be acquired as soon as possible (2-3 min) after injection. Planar static imaging (anterior and ipsilateral lateral views) of the ipsilateral breast and axillary regions will be performed at 2 h ± 12 min, 3 h ± 18 min and 6 h ± 36 min, and SPECT/CT imaging (anterior view, ipsilateral lateral view, and tomographic scan) will be conducted at 18 h ± 120 min, for a total of 5 scans.

For the remaining subjects, procedures will be implemented based on the exploratory results from the aforementioned 8 subjects:

  1. For subjects undergoing same-day SLNB: 0.5 mCi of 99mTc-SC will be administered; SPECT/CT imaging will be performed at 2 h ± 12 min to 5 h ± 30 min after dosing, and SLNB will be conducted at 3-6 h ± 36 min after dosing.
  2. For subjects undergoing next-day SLNB: 1 mCi of 99mTc-SC will be administered; SPECT/CT imaging will be performed at 3 h ± 30 min to 18 h ± 120 min after dosing, and SLNB will be completed within 18 h ± 120 min after dosing.

Technetium Tc 99m Sulfur Colloid Injection will be injected subcutaneously over the tumor surface. For subjects with an excisional biopsy cavity, or with tumors located in the upper outer quadrant close to the axilla which may interfere with imaging, subareolar injection is recommended (surgeons are advised to perform preoperative skin marking based on clinical conditions and confirm the appropriate injection site through consultation with the nuclear medicine department).

Approximately 15 minutes before surgery, all subjects will receive 0.5-2 mL (5.0 mg/mL) of Mitoxantrone Hydrochloride Injection for Tracing. For subjects undergoing total mastectomy, the injection will be administered subcutaneously around the tumor or posterior to the areola; for subjects undergoing breast-conserving surgery, the injection will be administered via two deep peritumoral subcutaneous injection points or a single point with multi-directional injection (intradermal injection and injection into the areolar area are strictly prohibited). After injection, the injection site will be massaged for 5-8 minutes, followed by sentinel lymph node biopsy.

A hand-held gamma probe will then be used to locate "hot spot" lymph nodes and mark their surface positions. An incision will be made along the skin crease over the "hot spot" lymph node, or via the total mastectomy surgical incision, to perform SLNB. Guided by the hand-held gamma probe within the incision, "hot spot" lymph nodes will be resected until no further "hot spots" are detected (radioactive count no higher than 1/10 of the maximum ex vivo SLN count). Meanwhile, blue-stained lymph nodes will be identified and removed. Subsequently, total mastectomy or breast-conserving surgery will be performed, and all blue-stained tissues will be resected as thoroughly as possible intraoperatively.

Resected lymph nodes with radioactive uptake and/or blue staining are defined as SLNs. Clinically suspicious lymph nodes that are neither "hot spots" nor blue-stained will also be resected and labeled separately.

The in vivo radioactive counts of "hot spots" and ex vivo radioactive counts of SLNs will be recorded. The following quantities will all be documented: the number of SLNs positive for both radioactive "hot spot" and blue staining, the number of SLNs positive only for radioactive "hot spot", the number positive only for blue staining, and the number of suspicious SLNs negative for both radioactive "hot spot" and blue staining.

Both intraoperative pathological diagnosis and postoperative pathological diagnosis of breast cancer SLNs are acceptable in this study. Pathological examination will be performed in accordance with the standard procedures of each investigational center, and the pathological diagnosis of each sentinel lymph node will be recorded.

  • Intraoperative pathological examination: Intraoperative SLN specimens will be sectioned into 2 mm-thick frozen sections. A portion of the tissue will be used for intraoperative histopathological examination with hematoxylin and eosin (HE) staining; the remaining tissue sections will be processed for routine paraffin pathological examination after surgery, with HE staining and immunohistochemistry (IHC, if indicated). In case of discrepancy between intraoperative and postoperative pathology for an individual subject, the positive pathological result shall prevail.
  • Postoperative pathological examination: All resected SLN tissues will be sampled and prepared into paraffin-embedded sections, sectioned at 2 mm thickness, and subjected to HE staining and immunohistochemistry (if indicated).

SLN metastasis will be classified according to the AJCC Cancer Staging Manual, 8th Edition. In this study, a positive SLN is defined as metastatic foci with a maximum diameter > 0.2 mm detected by histological examination or immunohistochemistry. A positive subject refers to a patient in whom at least one positive SLN is identified.

03

Conditions studied

  • Sentinel Nodes
  • Breast Cancer

Browse trials for

Keywords

  • Technetium Tc 99m Sulfur Colloid Injection
  • Sentinel Nodes
  • Breast Cancer
  • Self-Controlled Clinical Trial
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria

  1. Able to understand and voluntarily sign a written .
  2. Female subjects aged 18-70 years ( including 18 and 70 years ).
  3. confirmed diagnosis of invasive breast cancer or primary invasive breast cancer or ductal carcinoma in situ (DCIS) ;
  4. Clinical stage 1 or 2;
  5. For subjects undergoing surgical treatment, axillary sentinel lymph node is part of the surgical plan;
  6. The axillary lymph nodes were negative by imaging examination or confirmed by fine needle aspiration.
  7. Conventional preoperative examination showed no clear surgical Exclusion criteria

1)Participants are allergic to the test drug or its or have a history of severe drug allergy ; 2)Participants with prior surgery for breast cancer or chemotherapy ; 3)inflammatory breast cancer ; 4)Ipsilateral axillary clinical examination or imaging examination positive or puncture lymph node pathology positive, no breast cancer histopathological diagnosis or no puncture pathological examination ; 5)Have received any form of breast augmentation surgery ; 6)Participants with liver or kidney dysfunction, , AST>2.5 times , >1.5 times ULN, Serum creatinine >1.5 times, or Investigators believe that liver and / or kidney damage to the extent that patients should not participate in this study;; 7)With serious or uncontrollable diseases : such as severe cardiovascular and cerebrovascular diseases ( blood disease, chronic congestive heart failure classification ≥ III level, etc. ), severe pulmonary insufficiency ( one second rate / FVC \< 50 % or FEV1 \< 50 % predicted value or maximum ventilation volume per minute MVV \< 50L / min ), psychiatric patients ; 8)Participants with active infection of infectious diseases screening ( surface antigen, antibody, syphilis antibody, antibody ) ; 9)participated in clinical trials of other drugs within 3 months before screening; 10)) Patients with positive pregnancy test or pregnancy plan during lactation or screening period to 3 months after administration and unwilling to take effective measures or egg donation plan; 11)Investigators considered that it was not suitable for the patients to participate in this trial

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    Experimental: 99mTc-SC and MHI Intra-individual Control Group

    All enrolled patients will receive both Technetium \[99mTc\] Sulfur Colloid Injection (99mTc-SC) and Mitoxantrone Hydrochloride Injection for Tracer (MHI) as intra-individual controls prior to sentinel lymph node biopsy (SLNB). 1. 99mTc-SC Administration: Administered subcutaneously (peritumoral or subareolar) 3 to 18 hours prior to surgery. The dosage is scheduled based on surgery timing: Same-day SLNB: 0.5 mCi 99mTc-SC injected 3 to 6 hours (±36 min) before SLNB. Next-day SLNB: 1.0 mCi 99mTc-SC injected 3 to 18 hours (±120 min) before SLNB. 2. MHI Administration: 0.5 to 2.0 mL (5.0 mg/mL) of MHI is injected subcutaneously (peritumoral or deep subcutaneous) approximately 15 minutes before SLNB, followed by local massage for 5 to 8 minutes. Sentinel lymph nodes (SLNs) will be localized and identified intraoperatively using a handheld gamma detector probe (hot spots) and visual inspection for blue staining.

    Drug: Technetium Tc 99m Sulfur Colloid Injection · Drug: Mitoxantrone Hydrochloride Injection for Tracing

Interventions

  • DrugTechnetium Tc 99m Sulfur Colloid Injection

    Technetium \[99mTc\] Sulfur Colloid Injection (0.1-1.0 mCi; specifically 0.5 mCi for same-day surgery administered 3-6 hours prior to SLNB, or 1.0 mCi for next-day surgery administered 3-18 hours prior to SLNB) is administered via subcutaneous injection over the tumor surface (or subareolar region in cases with biopsy cavities or upper-outer quadrant tumors near the axilla). Preoperative SPECT/CT imaging is performed. Intraoperatively, a handheld gamma detector probe (GDP) is used to identify and locate "hot spot" sentinel lymph nodes (SLNs).

    Also known as: 99mTc-SC

  • DrugMitoxantrone Hydrochloride Injection for Tracing

    Mitoxantrone Hydrochloride Injection for Tracing (0.5-2.0 mL, 5.0 mg/mL) is administered approximately 15 minutes prior to surgery via subcutaneous injection around the tumor or behind the areola for total mastectomy, or deep peritumoral subcutaneous injection for breast-conserving surgery, followed by local massage for 5-8 minutes. Intraoperatively, blue-stained lymph nodes and/or blue lymphatic channels pointing to lymph nodes are visually identified as SLNs

    Also known as: MHI

06

What researchers measure

Primary outcomes

  1. Sentinel lymph node detection rate.

    Time frame: During surgery (Day 0 or Day 1))

Secondary outcomes

  1. The consistency between 99mTc-SC and MHI

    Time frame: Intraoperatively during sentinel lymph node biopsy (Day 0 or Day 1)

  2. The coincidence between 99mTc-SC and MHI

    Time frame: Up to 14 days post-surgery (Day 14 ± 3)

  3. Observe the incidence and severity of adverse events ( AE ) and severe adverse events ( SAE ), as well as abnormal laboratory test indicators.

    Time frame: From study drug administration through 14 days post-surgery (Day 14 ± 3)

Other outcomes

  1. Explore the effect of pretreatment time before 99mTc-SC on the detection rate

    Time frame: Intraoperatively during sentinel lymph node biopsy (Day 0 or Day 1)

  2. Explore the rationality of the positive threshold of hand-held gamma probe for sentinel lymph node radioactive counts.

    Time frame: Up to 14 days post-surgery (Day 14 ± 3)

07

Study locations

1 site
  • Peking University Cancer Hospital
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jun 2025, 17 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 17 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Aug 14, 2026
StartActual
Jan 2, 2024
Primary completionActual
Jun 3, 2025
CompletionActual
Jun 3, 2025
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764653
Lead sponsor
HTA Co., Ltd.
Responsible party
Sponsor
First posted
Aug 14, 2026
Start date
Jan 2, 2024
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Last update
Aug 14, 2026

Study contacts

Zaoqing Fan, MD
principal investigator · Peking University Cancer Hospital & Institute
Zhi Yang, MD
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion